Editor’s Note, October 24, 2013
Dear Subscriber, In the coming weeks we will be providing short profiles of selected companies presenting at the 7th Annual OneMedForum in San Francisco on […]
ISTO’s Cell Therapies Can Revolutionize Treatment of Joint, Bone Injuries
ISTO Technologies, Inc.is both a regenerative medicine and orthopedics company developing innovative cartilage and bone regeneration products for spinal therapy, sports medicine and trauma. ISTO is currently focused on the development of cell-based cartilage platform technology that can be applied to repair and regenerate damaged cartilage in the knee and spinal disc.
Aridis Pharmaceuticals: Better Alternative to Traditional Antibiotics?
Aridis Pharmaceuticals is a private biotechnology company focusing on improved alternatives to traditional antibiotics for the treatment of pneumonia and Cystic Fibrosis in addition to a few other conditions.
“Regulatory Rush”-The SEC Lifts The Ban On General Solicitation
On July 10th, 2013 new changes to regulations regarding the general solicitation of securities was announced by the Securities and Exchange Commission as the enactment […]
OneMedForum Recap: Del Mar Pharmaceuticals
Delmar Pharmaceuticals (DMPI) is a clinical and early stage Oncologyl Company focused on developing and commercializing leading anti-cancer therapies in high impact orphan oncological indications specifically where patients have failed contemporary therapy.
OneMedForum Recap: Pressure Biosciences
Pressure Biosciences (PBIO) is a life sciences company centered on developing and commercializing a novel technology titled Pressure Cycling Technology (PCT).
The Fly on the Wall: Athersys Publishes Study on Increasing Survival of Organ Transplants With Stem Cells
Athersys (ATHX) is a clinical stage based biopharmaceutical company with an exponentially growing pipeline and an array of products in therapeutics to treat significant and life-threatening diseases.
PR Newswire: BioDelivery Sciences International Secures $20 Million in Debt Financing
A company to keep a look out for in the upcoming future is BioDelivery Sciences International (BDSI), a specialty pharmaceutical company with a platform of drug delivery technologies to develop, commercialize, and improve already proven applications of therapeutics.
Global News Wire: Pluristem Therapeutics Forms Strategic Alliance with ChaBio & Diostech
Pluristem Therapeutics (PSTI) is a developer of placenta-based cell therapies. They have just formed a strategic alliance with Cha Bio&Diostech.